{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:09:22Z","timestamp":1788268162497,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deletions or mutations in the\n                    <jats:italic>Survival Motor Neuron 1<\/jats:italic>\n                    gene, associated with high morbidity and mortality related to muscle weakness. In recent years, the availability of new disease-modifying therapies and the extension of newborn screening has brought radical changes in the natural history of SMA at all ages. Historically, the classification of SMA has been based on age of onset and achievement of maximum motor milestone. In this new era, the historical classification of SMA by typology is no longer adequate to define the prognosis and type of SMA, nor to guide clinical management and treatment choice. The aim of this work is to discuss the current status of SMA neonatal screening and access to therapies across Europe and propose a new updated nomenclature, more suitable to guide clinicians in the management of SMA patients in the era of newborn screening. In this perspective, we evaluate and analyze the genetic basis of the disease, the current therapeutic landscape, the possible genotypic\/phenotypic scenarios and the related clinical management.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2025.1542396","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:10:32Z","timestamp":1746576632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Spinal muscular atrophy in the era of newborn screening: how the classification could change"],"prefix":"10.3389","volume":"16","author":[{"given":"Antonio","family":"Varone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bitetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","article-title":"A multi-source approach to determine SMA incidence and research ready population","volume":"264","author":"Verhaart","year":"2017","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1212\/WNL.0000000000201654","article-title":"Prevalence of spinal muscular atrophy in the era of disease-modifying therapies: an Italian Nationwide survey","volume":"100","author":"Coratti","year":"2023","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/ijns10030049","article-title":"Systematic review of newborn screening Programmes for spinal muscular atrophy","volume":"10","author":"Cooper","year":"2024","journal-title":"Int J Neonatal Screen"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 November 2014, Heemskerk","volume":"25","author":"Finkel","year":"2015","journal-title":"NMD"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution","volume":"5","author":"Dubowitz","year":"1995","journal-title":"NMD"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3390\/ijms24032247","article-title":"The SMN complex at the crossroad between RNA metabolism and neurodegeneration","volume":"24","author":"Faravelli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/genes12091346","article-title":"Alternative splicing role in new therapies of spinal muscular atrophy","volume":"12","author":"Lejman","year":"2021","journal-title":"Genes (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front Mol Biosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603.eCollection","article-title":"Spinal muscular atrophy: mutations, testing, and clinical relevance","volume":"2021","author":"Keinath","year":"2021","journal-title":"Appl Clin Genet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","article-title":"Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy","volume":"28","author":"De Sanctis","year":"2018","journal-title":"NMD"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.braindev.2008.08.012","article-title":"Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy","volume":"31","author":"Watihayati","year":"2009","journal-title":"Brain and Development"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.3390\/ijms23158289","article-title":"Deep molecular characterization of milder spinal muscular atrophy patients carrying the c.859G>C variant in SMN2","volume":"23","author":"Blasco-P\u00e9rez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1515\/cclm-2013-0209","article-title":"Prenatal molecular diagnosis of inherited neuromuscular diseases: Duchenne\/Becker muscular dystrophy, myotonic dystrophy type 1 and spinal muscular atrophy","volume":"51","author":"Esposito","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.1073\/pnas.88.16.7276","article-title":"Detection of specific polymerase chain reaction product by utilizing the 5\u2032----3\u2032 exonuclease activity of Thermus aquaticus DNA polymerase","volume":"88","author":"Holland","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jmoldx.2021.03.004","article-title":"Multisite evaluation and validation of a sensitive diagnostic and screening system for spinal muscular atrophy that reports SMN1 and SMN2 copy number, along with disease modifier and gene duplication variants","volume":"23","author":"Milligan","year":"2021","journal-title":"J Mol Diagn"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nmd.2024.03.005","article-title":"Rare homozygous disease-associated sequence variants in children with spinal muscular atrophy: a phenotypic description and review of the literature","volume":"37","author":"Li","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","article-title":"One year of newborn screening for SMA \u2013 results of a German pilot project","volume":"6","author":"Vill","year":"2019","journal-title":"J Neuromuscul Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1212\/WNL.96.15_supplement.4281","article-title":"P.362RAINBOWFISH: a study of risdiplam (RG7916) in newborns with pre-symptomatic spinal muscular atrophy (SMA)","volume":"29","author":"Richard","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"ref23","year":"2017"},{"key":"ref24","article-title":"The community statement-9th September 2020","year":"2020"},{"key":"ref25","article-title":"Evrysdi (Risdiplam)","year":"2021"},{"key":"ref26","year":"2020"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s13023-024-03326-3","article-title":"Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment","volume":"19","author":"Desguerre","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.lanepe.2023.100817","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"ref29","year":"2025"},{"key":"ref30","article-title":"SMA NBS Alliance white paper, December 12","year":"2024"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/ana.26788","article-title":"Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable?","volume":"94","author":"Ricci","year":"2023","journal-title":"Ann Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40246-024-00676-8","article-title":"Evaluating the clinical efficacy of a long-read sequencing- based approach for carrier screening of spinal muscular atrophy","volume":"18","author":"Long","year":"2024","journal-title":"Hum Genomics"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1515\/cclm-2024-0334","article-title":"Analytical validation of the amplification refractory mutation system polymerase chain reaction-capillary electrophoresis assay to diagnose spinal muscular atrophy","volume":"62","author":"Yao","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acn3.52018","article-title":"Early spinal muscular atrophy treatment following newborn screening: a 20-month review of the first Italian regional experience","volume":"11","author":"Gagliardi","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis","volume":"60","author":"Abiusi","year":"2023","journal-title":"J Med Genet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/j.spen.2021.100899","article-title":"Spinal muscular atrophy treatments, newborn screening, and the creation of a Neurogenetics urgency","volume":"38","author":"Butterfield","year":"2021","journal-title":"Semin Pediatr Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"S25.001","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study (S25.001)","volume":"92","author":"De Vivo","year":"2019","journal-title":"Neurology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1542396\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:10:32Z","timestamp":1746576632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1542396\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":37,"alternative-id":["10.3389\/fneur.2025.1542396"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1542396","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"article-number":"1542396"}}